In Changing RNAi Rx Guidance, Pfizer Becomes Latest Big Pharma to Shift Expectations
November 04, 2010
In Changing RNAi Rx Guidance, Pfizer Becomes Latest Big Pharma to Shift Expectations
At the same time, a handful of RNAi drug shops have found forging alliances with pharmaceutical firms to be challenging, in some cases missing previous partnership guidance on several occasions.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Calando, Others Miss 2010 Partnering Guidance as Industry Takes Sober View of RNAi
January 6, 2011 / Gene Silencing News - For Some RNAi Rx Shops, Industry Deals with Bigger Players are Par for the Course
August 20, 2009 / Gene Silencing News - RNAi Drugs Field Sees Candidate Failures as More Drugs Enter the Clinic
November 17, 2011 / Gene Silencing News - Merck Remains Committed to RNAi Despite Shuttering Its California Facility
August 4, 2011 / Gene Silencing News - Despite Recent Changes in Plans, Big Pharma Maintains RNAi Partnerships
December 9, 2010 / Gene Silencing News